The global triamcinolone acetonide nasal market is anticipated to grow at a significant CAGR of 4.5% during the forecast period 2022-2028. The growth of the market is attributed to the rising cases of nasal problems and other inflammatory disorders associated with allergies and asthma such as perennial allergic rhinitis. According to World Health Organization (WHO), asthma is a significant non-communicable disease (NCD) that affects both children and adults. In 2019, asthma afflicted an estimated 262 million individuals, resulting in 461000 fatalities. The most frequent chronic condition among children is asthma. Inhaled medicine can help patients with asthma manage their symptoms and live a normal, active life. According to NCBI, Allergic rhinitis is a chronic upper airway inflammatory disease that affects approximately 60 million adults and children in the US.
(Get 15% Discount on Buying this Report)
A full report is available at : https://orionmarketreports.com/global-triamcinolone-acetonide-nasal/92793/
The rising incidence of respiratory allergies, the ageing population, and technological improvements are some of the primary drivers driving demand for triamcinolone acetonide nasal treatments globally. In addition, the prevalence of asthma, COPD, and hay fever has increased significantly. Increased understanding of the numerous types of drugs available to treat sinusitis is predicted to have a substantial impact on the market. For instance, in January 2022, Glenmark Pharmaceuticals Ltd. announced that its fully-owned Swiss subsidiary Glenmark Specialty S.A. received approval for Ryaltris, a nasal spray fixed-dose prescription drug from the US Food and Drug Administration (FDA). It is used for the treatment of seasonal allergic rhinitis. For instance, in January 2021, JB Chemicals and Pharmaceuticals Ltd. announced that the US FDA has approved an abbreviated new drug application (ANDA) for Loratadine tablets USP 10 mg in the US market. The medication is used to treat pollen-induced allergic rhinitis and upper respiratory tract allergies.
Market Coverage
The market number available for – 2022-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Type
By Application
By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
Rest of the World
Competitive Landscape- Perrigo Co. PLC, Rising Pharma Holdings Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How are playersaddressing challenges to sustain growth?
- Where is the investment opportunity?
Global Triamcinolone Acetonide Nasal Market Report by Segment
By Type
- 200 mcg
- 400 mcg
By Application
- Adults
- Adolescents
By Distribution Channel
- Hospitals
- Drug Stores
- Others
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name : Orion Market Reports
Contact Person : Mr. Anurag Tiwari
Email : Info@orionmarketreports.com
Contact No : +91 780-304-0404
This release has been published on Global market Post
Global market Post is not responsible for any content included in this release.
